TY - JOUR T1 - Deep Learning to Estimate Cardiac Magnetic Resonance-Derived Left Ventricular Mass JF - medRxiv DO - 10.1101/2020.12.18.20248364 SP - 2020.12.18.20248364 AU - Shaan Khurshid AU - Samuel Friedman AU - James P. Pirruccello AU - Paolo Di Achille AU - Nathaniel Diamant AU - Christopher D. Anderson AU - Patrick T. Ellinor AU - Puneet Batra AU - Jennifer E. Ho AU - Anthony Philippakis AU - Steven A. Lubitz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/22/2020.12.18.20248364.abstract N2 - Background Cardiac magnetic resonance (CMR) is the gold standard for left ventricular hypertrophy (LVH) diagnosis. CMR-derived LV mass can be estimated using proprietary algorithms (e.g., inlineVF), but their accuracy and availability may be limited.Objective To develop an open-source deep learning model to estimate CMR-derived LV mass.Methods Within participants of the UK Biobank prospective cohort undergoing CMR, we trained two convolutional neural networks to estimate LV mass. The first (ML4Hreg) performed regression informed by manually labeled LV mass (available in 5,065 individuals), while the second (ML4Hseg) performed LV segmentation informed by inlineVF contours. We compared ML4Hreg, ML4Hseg, and inlineVF against manually labeled LV mass within an independent holdout set using Pearson correlation and mean absolute error (MAE). We assessed associations between CMR-derived LVH and prevalent cardiovascular disease using logistic regression adjusted for age and sex.Results We generated CMR-derived LV mass estimates within 38,574 individuals. Among 891 individuals in the holdout set, ML4Hseg reproduced manually labeled LV mass more accurately (r=0.864, 95% CI 0.847-0.880; MAE 10.41g, 95% CI 9.82-10.99) than ML4Hreg (r=0.843, 95% CI 0.823-0.861; MAE 10.51, 95% CI 9.86-11.15, p=0.01) and inlineVF (r=0.795, 95% CI 0.770-0.818; MAE 14.30, 95% CI 13.46-11.01, p<0.01). LVH defined using ML4Hseg demonstrated the strongest associations with hypertension (odds ratio 2.76, 95% CI 2.51-3.04), atrial fibrillation (1.75, 95% CI 1.37-2.20), and heart failure (4.53, 95% CI 3.16-6.33).Conclusions ML4Hseg is an open-source deep learning model providing automated quantification of CMR-derived LV mass. Deep learning models characterizing cardiac structure may facilitate broad cardiovascular discovery.Competing Interest StatementDr. Pirruccello has served as a consultant for Maze Therapeutics. Dr. Philippakis receives sponsored research support from Bayer AG, IBM, Intel, and Verily. He has also received consulted fees from Novartis and Rakuten. Dr. Ho receives sponsored research support from Bayer AG and Gilead Sciences. Dr. Ho has received research supplies from EcoNugenics. Dr. Friedman receives sponsored research support from Bayer AG and IBM. Dr. Anderson receives sponsored research support from Bayer AG and has consulted for ApoPharma, Inc. Dr. Batra receives sponsored research support from Bayer AG and IBM, and consults for Novartis. Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration with IBM. Dr. Ellinor receives sponsored research support from Bayer AG. Dr. Ellinor has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics.Funding StatementDr. Khurshid is supported by NIH T32HL007208. Dr. Pirruccello is supported by a John S. LaDue Memorial Fellowship. Dr. Ho is supported by NIH R01HL134893, R01HL140224, and K24HL153669. Dr. Lubitz is supported by NIH 1R01HL139731 and American Heart Association (AHA) 18SFRN34250007. Dr. Ellinor is supported by NIH 1R01HL092577, R01HL128914, K24HL105780, the American Heart Association 18SFRN34110082, and by the Foundation Leducq 14CVD01. Dr. Anderson is supported by NIH R01NS103924 and AHA 18SFRN34250007.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference number 11/NW/0382). Use of UK Biobank data (application 7089) was approved by the local Mass General Brigham Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel architectures, trained weights and more metrics are available at: https://github.com/broadinstitute/ml4h/tree/master/model_zoo/cardiac_mri_derived_left_ventricular_mass/. https://github.com/broadinstitute/ml4h/tree/master/model_zoo/cardiac_mri_derived_left_ventricular_mass/ ER -